← The ApothecaryHelodermatidaevenom / saliva (source of exendin-4; the drug is now made synthetically)Fact-checked 24 October 2026

Significant riskGila monster bites cause pain, low blood pressure, fast heart rate, nausea and vomiting; teeth left in the wound may not show on X-ray, and at least 6 hours' observation is advised. Severe reactions include angioedema, circulatory instability and heart attack, and a 2026 report described a death. Wild Gila monsters should not be handled.In an emergency, call your local emergency number or poison centre.

Gila monster

Heloderma suspectum

Also calledGila monster (English)

A venomous lizard of the deserts of the south-western United States and north-western Mexico. In 1992 exendin-4 was isolated from its venom, a peptide that mimics the gut hormone GLP-1 but resists breakdown; made synthetically as exenatide, it became in 2005 the first GLP-1 receptor agonist drug for type 2 diabetes and opened the way to today's GLP-1 medicines. The animal itself is protected and its bite is dangerous.

Full natural-history sheet →

What it is used for

Blood sugar and diabetes
Strong
Not the animal but its drug: exenatide (Byetta, twice-daily injection, FDA 2005; extended-release form 2012) is approved as an adjunct to diet and exercise to improve blood-sugar control in adults with type 2 diabetes. It raises insulin release only when glucose is high, suppresses glucagon and slows stomach emptying.^2,3,4
Weight
Moderate
Exenatide produces modest weight loss through reduced appetite, useful in overweight people with type 2 diabetes; its successor liraglutide is also marketed as Saxenda (2014). The lizard and its venom are not a weight-loss remedy.^3,4

Safety

Pregnancy: Insufficient data
Breastfeeding: Insufficient data
Children: Exenatide is licensed for adults.

Interactions with medicines

insulin and sulfonylureasMajorExenatide raises the risk of hypoglycaemia, sometimes severe; doses of these drugs may need lowering (FDA label).
warfarinModeratePost-marketing reports of raised INR, sometimes with bleeding; monitor more often (FDA label).
oral medicinesMinorSlowed stomach emptying may change their absorption (FDA label).

Interaction checker →

Do not use if

Exenatide: previous severe allergy to exenatide; previous exenatide-induced immune thrombocytopenia (FDA label)
Exenatide: not recommended in severe gastroparesis

Side effects

Exenatide: nausea (usually easing), vomiting, diarrhoea, hypoglycaemia, jitteriness, dizziness, headache, indigestion, constipation
Exenatide: rare acute pancreatitis, acute kidney injury from dehydration, gallbladder disease, anaphylaxis, immune thrombocytopenia

In the healing traditions

Indigenous North American
Gila monster
Revered in Navajo culture and folklore long before its medical value was known.
Dyson et al. 2026 (abstract)
Modern pharmacology
Exendin-4 → exenatide
A 39-amino-acid peptide with about 53% similarity to human GLP-1 but resistant to the enzyme DPP-4, giving a half-life of about 2.5 hours instead of 1–2 minutes; it led to the GLP-1 receptor agonist class (exenatide, liraglutide, semaglutide).

Active compounds

exendin-4: 39-amino-acid venom peptide; GLP-1 receptor agonist; synthetic form is exenatide
exendin-(9-39): truncated peptide that blocks the GLP-1 receptor; a research tool

History

A 1982 study described the action of Gila monster venom on pancreatic cells. In 1992 Eng and colleagues at the Bronx Veterans Affairs Medical Center isolated exendin-4 from the venom, and in 1993 it was shown to be a potent agonist at the GLP-1 receptor. Because native GLP-1 lasts only 1–2 minutes in the blood, the DPP-4-resistant lizard peptide was developed into exenatide, approved by the FDA in 2005 as the first drug of the class that now includes liraglutide and semaglutide.

Sources

Reference, not prescription. Nothing here is medical advice. Herbs can interact with medicines and be dangerous in pregnancy; tell your doctor or pharmacist about anything you take.